Disc Medicine, Inc.
IRON- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001816736
In the last 90 days, Disc Medicine, Inc. insiders filed 0 open-market purchases and 6 sales; 235 institutions reported holding it in 13F filings for Q3 2026, worth $2.86B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:59 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 27, 2025 | Mar 21, 2024 | Mar 31, 2023 | Mar 10, 2022 |
| Operating expenses | $236.0M | $129.7M | $91.1M | $47.5M | $69.0M |
| Research and development | $170.6M | $96.7M | $69.3M | $33.4M | $48.7M |
| Selling, general and administrative | $65.4M | $33.0M | $21.9M | $14.0M | $20.3M |
| Operating income | -$236.0M | -$129.7M | -$91.1M | -$47.5M | -$69.0M |
| Interest expense | – | – | – | – | $2.16M |
| Income tax | $361.0K | $355.0K | $99.0K | – | – |
| Net income | -$212.2M | -$109.4M | -$76.4M | -$46.8M | -$71.9M |
| EPS, basic | $-6.01 | $-3.96 | $-3.42 | $-45.05 | – |
| EPS, diluted | $-6.01 | $-3.96 | $-3.42 | $-45.05 | – |
| Weighted shares, basic | 35.3M | 27.6M | 22.3M | 1.04M | – |
| Weighted shares, diluted | 35.3M | 27.6M | 22.3M | 1.04M | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 27, 2025 | Mar 21, 2024 | Mar 31, 2023 | Mar 10, 2022 |
| Cash and equivalents | $91.1M | $192.4M | $360.4M | $194.6M | $136.6M |
| Short-term investments | $700.0M | $297.4M | – | – | – |
| Total current assets | $803.9M | $493.6M | $365.7M | $198.5M | $140.1M |
| Property, plant and equipment | $1.16M | $751.0K | $170.0K | $168.0K | $0 |
| Total assets | $806.9M | $496.8M | $368.0M | $200.2M | $140.4M |
| Accounts payable | $9.02M | $7.95M | $12.6M | $16.2M | $2.95M |
| Total current liabilities | $36.6M | $23.3M | $21.4M | $22.6M | $14.8M |
| Long-term debt | $29.2M | $28.3M | – | – | – |
| Total liabilities | $67.1M | $53.2M | $22.9M | $23.6M | $15.6M |
| Shareholders' equity | $739.8M | $443.6M | $345.1M | $176.6M | $124.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Feb 27, 2025 | Mar 21, 2024 | Mar 31, 2023 | Mar 10, 2022 |
| Operating cash flow | -$180.4M | -$93.9M | -$73.5M | -$42.3M | -$59.7M |
| Capital expenditures | $933.0K | $505.0K | $89.0K | $151.0K | $71.0K |
| Free cash flow | -$181.3M | -$94.4M | -$73.6M | -$42.4M | -$59.8M |
| Depreciation and amortization | $281.0K | $156.0K | $100.0K | $89.0K | – |
| Stock-based compensation | $34.3M | $16.8M | $5.53M | $2.09M | $7.79M |
| Investing cash flow | -$394.3M | -$292.3M | -$89.0K | -$151.0K | $344.0K |
| Financing cash flow | $473.4M | $218.3M | $239.4M | $149.0M | $191.5M |
| Net change in cash | -$101.3M | -$167.9M | $165.8M | $106.6M | $132.1M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 29, 2026 | 45.5M | +20.6% | SEC |
| Jul 23, 2026 | 38.4M | +10.4% | SEC |
| Apr 30, 2026 | 38.2M | +10.3% | SEC |
| Feb 19, 2026 | 38.2M | +10.4% | SEC |
| Oct 31, 2025 | 37.8M | +26.9% | SEC |
| Jul 31, 2025 | 34.8M | +17.0% | SEC |
| Apr 30, 2025 | 34.6M | +40.1% | SEC |
| Feb 21, 2025 | 34.6M | +40.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-10 in Q4 2022.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.